Review



ucsd aml1  (DSMZ)


Bioz Verified Symbol DSMZ is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    DSMZ ucsd aml1
    EBD-300 enhances the anti-leukemic activity of VEN in AML cell lines. (A) Western blot analysis (n=1) reveals lower ASNS protein levels in deletion 7 cell lines (OCI-AML6 and <t>UCSD-AML1)</t> compared to non-deletion 7 cell lines (MOLM-13 and THP-1). (B) Fluorescence in situ hybridization (FISH) analysis shows that all six OCI-AML6 nuclei have only one red (RELN) and one green (TES) fluorescence signal, indicating potential monosomy of chromosome 7 or a deletion in the 7q region. In contrast, all three MOLM-13 nuclei show two pairs of bright fluorescent spots, confirming the presence of both copies of 7q. (C) The cell lines (n=3, technical replicates) were treated with VEH, VEN, or VEN+EBD-300 (0.5 IU/mL) for 96 hours after that Cell titer glo (CTG) assay was used to evaluate cell death. EBD-300 enhances the anti-leukemic effect of VEN in MOLM-13, reducing the VEN IC-50 from 0.0240 µM to 0.0128 µM, and in THP-1, reducing the VEN IC-50 from 5.21 µM to 1.72 µM. OCI-AML6 showed high sensitivity to EBD-300 (IC-50 of 1.1e-4 U/mL), while UCSD-AML1 was resistant to EBD-300. However, EBD-300 still enhanced the anti-leukemic effect of VEN in UCSD-AML1, reducing the VEN IC-50 from 4.34 µM to 2.11 µM. The error bars shown represent the Standard Error of mean or (SEM). *= <0.05, **= <0.01, ***= <0.001, ****= <0.0001.
    Ucsd Aml1, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ucsd+aml1/UCSD-AML1/pmc12930363-166-2-6
    Average 94 stars, based on 10 article reviews
    ucsd aml1 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion"

    Article Title: A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion

    Journal: Frontiers in Oncology

    doi: 10.3389/fonc.2025.1606239

    EBD-300 enhances the anti-leukemic activity of VEN in AML cell lines. (A) Western blot analysis (n=1) reveals lower ASNS protein levels in deletion 7 cell lines (OCI-AML6 and UCSD-AML1) compared to non-deletion 7 cell lines (MOLM-13 and THP-1). (B) Fluorescence in situ hybridization (FISH) analysis shows that all six OCI-AML6 nuclei have only one red (RELN) and one green (TES) fluorescence signal, indicating potential monosomy of chromosome 7 or a deletion in the 7q region. In contrast, all three MOLM-13 nuclei show two pairs of bright fluorescent spots, confirming the presence of both copies of 7q. (C) The cell lines (n=3, technical replicates) were treated with VEH, VEN, or VEN+EBD-300 (0.5 IU/mL) for 96 hours after that Cell titer glo (CTG) assay was used to evaluate cell death. EBD-300 enhances the anti-leukemic effect of VEN in MOLM-13, reducing the VEN IC-50 from 0.0240 µM to 0.0128 µM, and in THP-1, reducing the VEN IC-50 from 5.21 µM to 1.72 µM. OCI-AML6 showed high sensitivity to EBD-300 (IC-50 of 1.1e-4 U/mL), while UCSD-AML1 was resistant to EBD-300. However, EBD-300 still enhanced the anti-leukemic effect of VEN in UCSD-AML1, reducing the VEN IC-50 from 4.34 µM to 2.11 µM. The error bars shown represent the Standard Error of mean or (SEM). *= <0.05, **= <0.01, ***= <0.001, ****= <0.0001.
    Figure Legend Snippet: EBD-300 enhances the anti-leukemic activity of VEN in AML cell lines. (A) Western blot analysis (n=1) reveals lower ASNS protein levels in deletion 7 cell lines (OCI-AML6 and UCSD-AML1) compared to non-deletion 7 cell lines (MOLM-13 and THP-1). (B) Fluorescence in situ hybridization (FISH) analysis shows that all six OCI-AML6 nuclei have only one red (RELN) and one green (TES) fluorescence signal, indicating potential monosomy of chromosome 7 or a deletion in the 7q region. In contrast, all three MOLM-13 nuclei show two pairs of bright fluorescent spots, confirming the presence of both copies of 7q. (C) The cell lines (n=3, technical replicates) were treated with VEH, VEN, or VEN+EBD-300 (0.5 IU/mL) for 96 hours after that Cell titer glo (CTG) assay was used to evaluate cell death. EBD-300 enhances the anti-leukemic effect of VEN in MOLM-13, reducing the VEN IC-50 from 0.0240 µM to 0.0128 µM, and in THP-1, reducing the VEN IC-50 from 5.21 µM to 1.72 µM. OCI-AML6 showed high sensitivity to EBD-300 (IC-50 of 1.1e-4 U/mL), while UCSD-AML1 was resistant to EBD-300. However, EBD-300 still enhanced the anti-leukemic effect of VEN in UCSD-AML1, reducing the VEN IC-50 from 4.34 µM to 2.11 µM. The error bars shown represent the Standard Error of mean or (SEM). *= <0.05, **= <0.01, ***= <0.001, ****= <0.0001.

    Techniques Used: Activity Assay, Western Blot, Fluorescence, In Situ Hybridization, CTG Assay

    Related Articles

    other:

    Article Title: Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high‐risk MECOM‐rearranged AML
    Article Snippet: UCSD‐AML1 [DSMZ Cat# ACC‐691, RRID:CVCL_1853] cells were obtained from the DSMZ.

    Cell Culture:

    Article Title: Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
    Article Snippet: AML with chromosomal alterations involving 3q26 overexpresses the transcription factor (TF) EVI1, associated with therapy refractoriness and inferior overall survival in AML.. Consistent with a CRISPR screen highlighting BRD4 dependency, treatment with BET inhibitor (BETi) repressed EVI1, LEF1, c-Myc, c-Myb, CDK4/6, and MCL1, and induced apoptosis of AML cells with 3q26 lesions.. Tegavivint (TV, BC-2059), known to disrupt the binding of nuclear β-catenin and TCF7L2/LEF1 with TBL1, also inhibited colocalization of EVI1 with TBL1 and dose-dependently induced apoptosis in AML cell lines and patient-derived (PD) AML cells with 3q26.2 lesions.



    Similar Products

    atcc crl 2725 ucsd aml1 cells  (ATCC)
    95
    ATCC atcc crl 2725 ucsd aml1 cells
    Atcc Crl 2725 Ucsd Aml1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ucsd+aml1/Kasumi-3/pmc10791743__41467_2024_44698_MOESM2_ESM-43-21-21
    Average 95 stars, based on 1 article reviews
    atcc crl 2725 ucsd aml1 cells - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    ucsd aml1  (DSMZ)
    94
    DSMZ ucsd aml1
    EBD-300 enhances the anti-leukemic activity of VEN in AML cell lines. (A) Western blot analysis (n=1) reveals lower ASNS protein levels in deletion 7 cell lines (OCI-AML6 and <t>UCSD-AML1)</t> compared to non-deletion 7 cell lines (MOLM-13 and THP-1). (B) Fluorescence in situ hybridization (FISH) analysis shows that all six OCI-AML6 nuclei have only one red (RELN) and one green (TES) fluorescence signal, indicating potential monosomy of chromosome 7 or a deletion in the 7q region. In contrast, all three MOLM-13 nuclei show two pairs of bright fluorescent spots, confirming the presence of both copies of 7q. (C) The cell lines (n=3, technical replicates) were treated with VEH, VEN, or VEN+EBD-300 (0.5 IU/mL) for 96 hours after that Cell titer glo (CTG) assay was used to evaluate cell death. EBD-300 enhances the anti-leukemic effect of VEN in MOLM-13, reducing the VEN IC-50 from 0.0240 µM to 0.0128 µM, and in THP-1, reducing the VEN IC-50 from 5.21 µM to 1.72 µM. OCI-AML6 showed high sensitivity to EBD-300 (IC-50 of 1.1e-4 U/mL), while UCSD-AML1 was resistant to EBD-300. However, EBD-300 still enhanced the anti-leukemic effect of VEN in UCSD-AML1, reducing the VEN IC-50 from 4.34 µM to 2.11 µM. The error bars shown represent the Standard Error of mean or (SEM). *= <0.05, **= <0.01, ***= <0.001, ****= <0.0001.
    Ucsd Aml1, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ucsd+aml1/UCSD-AML1/pmc12930363-166-2-6
    Average 94 stars, based on 1 article reviews
    ucsd aml1 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    cell culture ucsd aml1  (DSMZ)
    94
    DSMZ cell culture ucsd aml1
    EBD-300 enhances the anti-leukemic activity of VEN in AML cell lines. (A) Western blot analysis (n=1) reveals lower ASNS protein levels in deletion 7 cell lines (OCI-AML6 and <t>UCSD-AML1)</t> compared to non-deletion 7 cell lines (MOLM-13 and THP-1). (B) Fluorescence in situ hybridization (FISH) analysis shows that all six OCI-AML6 nuclei have only one red (RELN) and one green (TES) fluorescence signal, indicating potential monosomy of chromosome 7 or a deletion in the 7q region. In contrast, all three MOLM-13 nuclei show two pairs of bright fluorescent spots, confirming the presence of both copies of 7q. (C) The cell lines (n=3, technical replicates) were treated with VEH, VEN, or VEN+EBD-300 (0.5 IU/mL) for 96 hours after that Cell titer glo (CTG) assay was used to evaluate cell death. EBD-300 enhances the anti-leukemic effect of VEN in MOLM-13, reducing the VEN IC-50 from 0.0240 µM to 0.0128 µM, and in THP-1, reducing the VEN IC-50 from 5.21 µM to 1.72 µM. OCI-AML6 showed high sensitivity to EBD-300 (IC-50 of 1.1e-4 U/mL), while UCSD-AML1 was resistant to EBD-300. However, EBD-300 still enhanced the anti-leukemic effect of VEN in UCSD-AML1, reducing the VEN IC-50 from 4.34 µM to 2.11 µM. The error bars shown represent the Standard Error of mean or (SEM). *= <0.05, **= <0.01, ***= <0.001, ****= <0.0001.
    Cell Culture Ucsd Aml1, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ucsd+aml1/UCSD-AML1/pm41419608-49-3-6
    Average 94 stars, based on 1 article reviews
    cell culture ucsd aml1 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    ucsd aml1 cells  (DSMZ)
    94
    DSMZ ucsd aml1 cells
    EBD-300 enhances the anti-leukemic activity of VEN in AML cell lines. (A) Western blot analysis (n=1) reveals lower ASNS protein levels in deletion 7 cell lines (OCI-AML6 and <t>UCSD-AML1)</t> compared to non-deletion 7 cell lines (MOLM-13 and THP-1). (B) Fluorescence in situ hybridization (FISH) analysis shows that all six OCI-AML6 nuclei have only one red (RELN) and one green (TES) fluorescence signal, indicating potential monosomy of chromosome 7 or a deletion in the 7q region. In contrast, all three MOLM-13 nuclei show two pairs of bright fluorescent spots, confirming the presence of both copies of 7q. (C) The cell lines (n=3, technical replicates) were treated with VEH, VEN, or VEN+EBD-300 (0.5 IU/mL) for 96 hours after that Cell titer glo (CTG) assay was used to evaluate cell death. EBD-300 enhances the anti-leukemic effect of VEN in MOLM-13, reducing the VEN IC-50 from 0.0240 µM to 0.0128 µM, and in THP-1, reducing the VEN IC-50 from 5.21 µM to 1.72 µM. OCI-AML6 showed high sensitivity to EBD-300 (IC-50 of 1.1e-4 U/mL), while UCSD-AML1 was resistant to EBD-300. However, EBD-300 still enhanced the anti-leukemic effect of VEN in UCSD-AML1, reducing the VEN IC-50 from 4.34 µM to 2.11 µM. The error bars shown represent the Standard Error of mean or (SEM). *= <0.05, **= <0.01, ***= <0.001, ****= <0.0001.
    Ucsd Aml1 Cells, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ucsd+aml1/UCSD-AML1/pmc10791743-287-0-5
    Average 94 stars, based on 1 article reviews
    ucsd aml1 cells - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    EBD-300 enhances the anti-leukemic activity of VEN in AML cell lines. (A) Western blot analysis (n=1) reveals lower ASNS protein levels in deletion 7 cell lines (OCI-AML6 and UCSD-AML1) compared to non-deletion 7 cell lines (MOLM-13 and THP-1). (B) Fluorescence in situ hybridization (FISH) analysis shows that all six OCI-AML6 nuclei have only one red (RELN) and one green (TES) fluorescence signal, indicating potential monosomy of chromosome 7 or a deletion in the 7q region. In contrast, all three MOLM-13 nuclei show two pairs of bright fluorescent spots, confirming the presence of both copies of 7q. (C) The cell lines (n=3, technical replicates) were treated with VEH, VEN, or VEN+EBD-300 (0.5 IU/mL) for 96 hours after that Cell titer glo (CTG) assay was used to evaluate cell death. EBD-300 enhances the anti-leukemic effect of VEN in MOLM-13, reducing the VEN IC-50 from 0.0240 µM to 0.0128 µM, and in THP-1, reducing the VEN IC-50 from 5.21 µM to 1.72 µM. OCI-AML6 showed high sensitivity to EBD-300 (IC-50 of 1.1e-4 U/mL), while UCSD-AML1 was resistant to EBD-300. However, EBD-300 still enhanced the anti-leukemic effect of VEN in UCSD-AML1, reducing the VEN IC-50 from 4.34 µM to 2.11 µM. The error bars shown represent the Standard Error of mean or (SEM). *= <0.05, **= <0.01, ***= <0.001, ****= <0.0001.

    Journal: Frontiers in Oncology

    Article Title: A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion

    doi: 10.3389/fonc.2025.1606239

    Figure Lengend Snippet: EBD-300 enhances the anti-leukemic activity of VEN in AML cell lines. (A) Western blot analysis (n=1) reveals lower ASNS protein levels in deletion 7 cell lines (OCI-AML6 and UCSD-AML1) compared to non-deletion 7 cell lines (MOLM-13 and THP-1). (B) Fluorescence in situ hybridization (FISH) analysis shows that all six OCI-AML6 nuclei have only one red (RELN) and one green (TES) fluorescence signal, indicating potential monosomy of chromosome 7 or a deletion in the 7q region. In contrast, all three MOLM-13 nuclei show two pairs of bright fluorescent spots, confirming the presence of both copies of 7q. (C) The cell lines (n=3, technical replicates) were treated with VEH, VEN, or VEN+EBD-300 (0.5 IU/mL) for 96 hours after that Cell titer glo (CTG) assay was used to evaluate cell death. EBD-300 enhances the anti-leukemic effect of VEN in MOLM-13, reducing the VEN IC-50 from 0.0240 µM to 0.0128 µM, and in THP-1, reducing the VEN IC-50 from 5.21 µM to 1.72 µM. OCI-AML6 showed high sensitivity to EBD-300 (IC-50 of 1.1e-4 U/mL), while UCSD-AML1 was resistant to EBD-300. However, EBD-300 still enhanced the anti-leukemic effect of VEN in UCSD-AML1, reducing the VEN IC-50 from 4.34 µM to 2.11 µM. The error bars shown represent the Standard Error of mean or (SEM). *= <0.05, **= <0.01, ***= <0.001, ****= <0.0001.

    Article Snippet: OCI-AML6 and UCSD-AML1 were purchased from DSMZ (Germany).

    Techniques: Activity Assay, Western Blot, Fluorescence, In Situ Hybridization, CTG Assay